Advertisement

Diagnostic Imaging and Image-Guided Interventions of Hepatobiliary Malignancies

  • Unni Udayasankar
  • Abbas Chamsuddin
  • Pardeep Mittal
  • William C. Small
Part of the Cancer Treatment and Research book series (CTAR, volume 143)

The unique histological characteristics, combined with a high vascularity and biochemical load, increase the vulnerability of hepatic tissue for the development of primary and metastatic tumors. The number of cases of hepatocellular carcinoma (HCC) has increased over the past two decades [1], and approximately 10,000 people are estimated to die annually from primary hepatic and biliary cancers in the United States [2]. Hepatic metastases contribute to mortality in a large number of patients. Recent advances in imaging techniques, including molecular and cellular biology, assist in early diagnosis, treatment and follow-up of hepatobiliary tumors [3-7]. Imaging plays an important role, since the diagnosis and management of many liver tumors has witnessed a sharp change in the last two decades. Imaging modalities such as ultrasound and computerized tomography (CT) are frequently used for staging cancer patients for hepatic metastatic tumor spread, and for evaluating patients with preexisting liver disease (chronic hepatitis or cirrhosis) to look for development of potential primary malignancies. Contrast-enhanced CT, magnetic resonance imaging (MRI) or molecular imaging techniques, including positron emission tomography (PET), are used to estimate the tumor burden, vascular or biliary invasion and residual normal liver volume. Imaging also facilitates diagnosis and treatment by guided procedures including percutaneous biopsy, radiofrequency ablation (RFA) and transarterial chemoembolisation (TACE).

Keywords

Arterial Phase Gallbladder Carcinoma Helical Computerize Tomography Focal Nodular Hyperplasia Portal Venous Phase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340(10):745-50.PubMedGoogle Scholar
  2. 2.
    Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55(1):10–30.PubMedGoogle Scholar
  3. 3.
    Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, Llovet JM. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene 2006;25(27):3848–56.PubMedGoogle Scholar
  4. 4.
    Korner M, Hayes GM, Rehmann R, et al. Secretin receptors in the human liver: expression in biliary tract and cholangiocarcinoma, but not in hepatocytes or hepatocellular carcinoma. Journal of hepatology 2006;45(6):825–35.PubMedGoogle Scholar
  5. 5.
    Libbrecht L. Hepatic progenitor cells in human liver tumor development. World J Gastroenterol 2006;12(39):6261–5.PubMedGoogle Scholar
  6. 6.
    Llovet JM, Chen Y, Wurmbach E, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006;131(6):1758–67.PubMedGoogle Scholar
  7. 7.
    Ramos E, Llado L, Serrano T, et al. Utility of cell-cycle modulators to predict vascular invasion and recurrence after surgical treatment of hepatocellular carcinoma. Transplantation 2006;82(6):753–8.PubMedGoogle Scholar
  8. 8.
    Haaga JR, Lanzieri CF, Gilkeson RC. CT and MRI of the whole body. 4th ed. St. Louis, Mo.: Mosby; 2003.Google Scholar
  9. 9.
    Bluemke DA, Soyer P, Fishman EK. Helical (spiral) CT of the liver. Radiologic clinics of North America 1995;33(5):863–86.PubMedGoogle Scholar
  10. 10.
    Scatarige JC, Fishman EK, Saksouk FA, Siegelman SS. Computed tomography of calcified liver masses. Journal of computer assisted tomography 1983;7(1):83–9.PubMedGoogle Scholar
  11. 11.
    Hale HL, Husband JE, Gossios K, Norman AR, Cunningham D. CT of calcified liver metastases in colorectal carcinoma. Clin Radiol 1998;53(10):735–41.PubMedGoogle Scholar
  12. 12.
    Chen MY, Bechtold RE, Savage PD. Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate). Ajr 2002;179(4):1059–62.PubMedGoogle Scholar
  13. 13.
    Soyer P, Poccard M, Boudiaf M, et al. Detection of hypovascular hepatic metastases at triple-phase helical CT: sensitivity of phases and comparison with surgical and histopathologic findings. Radiology 2004;231(2):413–20.PubMedGoogle Scholar
  14. 14.
    Kanematsu M, Kondo H, Goshima S, et al. Imaging liver metastases: review and update. Eur J Radiol 2006;58(2):217–28.PubMedGoogle Scholar
  15. 15.
    Blake SP, Weisinger K, Atkins MB, Raptopoulos V. Liver metastases from melanoma: detection with multiphasic contrast-enhanced CT. Radiology 1999;213(1):92–6.PubMedGoogle Scholar
  16. 16.
    Bressler EL, Alpern MB, Glazer GM, Francis IR, Ensminger WD. Hypervascular hepatic metastases: CT evaluation. Radiology 1987;162(1 Pt 1):49–51.PubMedGoogle Scholar
  17. 17.
    Sica GT, Ji H, Ros PR. CT and MR imaging of hepatic metastases. Ajr 2000;174(3):691–8.PubMedGoogle Scholar
  18. 18.
    Oliver JH, 3rd, Baron RL, Federle MP, Jones BC, Sheng R. Hypervascular liver metastases: do unenhanced and hepatic arterial phase CT images affect tumor detection? Radiology 1997;205(3):709–15.PubMedGoogle Scholar
  19. 19.
    Semelka RC, Hussain SM, Marcos HB, Woosley JT. Perilesional enhancement of hepatic metastases: correlation between MR imaging and histopathologic findings-initial observations. Radiology 2000;215(1):89–94.PubMedGoogle Scholar
  20. 20.
    Leslie DF, Johnson CD, MacCarty RL, Ward EM, Ilstrup DM, Harmsen WS. Single-pass CT of hepatic tumors: value of globular enhancement in distinguishing hemangiomas from hypervascular metastases. Ajr 1995;165(6):1403–6.PubMedGoogle Scholar
  21. 21.
    Leslie DF, Johnson CD, Johnson CM, Ilstrup DM, Harmsen WS. Distinction between cavernous hemangiomas of the liver and hepatic metastases on CT: value of contrast enhancement patterns. Ajr 1995;164(3):625–9.PubMedGoogle Scholar
  22. 22.
    Hanafusa K, Ohashi I, Himeno Y, Suzuki S, Shibuya H. Hepatic hemangioma: findings with two-phase CT. Radiology 1995;196(2):465–9.PubMedGoogle Scholar
  23. 23.
    Muramatsu Y, Takayasu K, Moriyama N, et al. Peripheral low-density area of hepatic tumors: CT-pathologic correlation. Radiology 1986;160(1):49–52.PubMedGoogle Scholar
  24. 24.
    Ichikawa T, Federle MP, Grazioli L, Madariaga J, Nalesnik M, Marsh W. Fibrolamellar hepatocellular carcinoma: imaging and pathologic findings in 31 recent cases. Radiology 1999;213(2):352–61.PubMedGoogle Scholar
  25. 25.
    Martin DR, Danrad R, Hussain SM. MR imaging of the liver. Radiologic clinics of North America 2005;43(5):861–86, viii.PubMedGoogle Scholar
  26. 26.
    Ichikawa T, Haradome H, Hachiya J, Nitatori T, Araki T. Diffusion-weighted MR imaging with a single-shot echoplanar sequence: detection and characterization of focal hepatic lesions. Ajr 1998;170(2):397–402.PubMedGoogle Scholar
  27. 27.
    Kim T, Murakami T, Takahashi S, Hori M, Tsuda K, Nakamura H. Diffusion-weighted single-shot echoplanar MR imaging for liver disease. Ajr 1999;173(2):393–8.PubMedGoogle Scholar
  28. 28.
    Namimoto T, Yamashita Y, Sumi S, Tang Y, Takahashi M. Focal liver masses: characterization with diffusion-weighted echo-planar MR imaging. Radiology 1997;204(3):739–44.PubMedGoogle Scholar
  29. 29.
    Taouli B, Vilgrain V, Dumont E, Daire JL, Fan B, Menu Y. Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. Radiology 2003;226(1):71–8.PubMedGoogle Scholar
  30. 30.
    Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002;224(3):748–56.PubMedGoogle Scholar
  31. 31.
    Zimmerman RL, Burke M, Young NA, Solomides CC, Bibbo M. Diagnostic utility of Glut-1 and CA 15–3 in discriminating adenocarcinoma from hepatocellular carcinoma in liver tumors biopsied by fine-needle aspiration. Cancer 2002;96(1):53–7.PubMedGoogle Scholar
  32. 32.
    Bohm B, Voth M, Geoghegan J, et al. Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors. Journal of cancer research and clinical oncology 2004;130(5):266–72.PubMedGoogle Scholar
  33. 33.
    Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK, Jr., Pinson CW. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998;133(5):510–5; discussion 5–6.PubMedGoogle Scholar
  34. 34.
    Vitola JV, Delbeke D, Sandler MP, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. American journal of surgery 1996;171(1):21–6.PubMedGoogle Scholar
  35. 35.
    Arulampalam TH, Francis DL, Visvikis D, Taylor I, Ell PJ. FDG-PET for the pre-operative evaluation of colorectal liver metastases. Eur J Surg Oncol 2004;30(3):286–91.PubMedGoogle Scholar
  36. 36.
    Schiepers C, Penninckx F, De Vadder N, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995;21(5):517–22.PubMedGoogle Scholar
  37. 37.
    Ogunbiyi OA, Flanagan FL, Dehdashti F, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997;4(8):613–20.PubMedGoogle Scholar
  38. 38.
    Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Annals of surgery 2004;240(3):438–47; discussion 47–50.PubMedGoogle Scholar
  39. 39.
    Khandani AH, Wahl RL. Applications of PET in liver imaging. Radiologic clinics of North America 2005;43(5):849–60, vii.PubMedGoogle Scholar
  40. 40.
    Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999;29(1):62–7.PubMedGoogle Scholar
  41. 41.
    Clark HP, Carson WF, Kavanagh PV, Ho CP, Shen P, Zagoria RJ. Staging and current treatment of hepatocellular carcinoma. Radiographics 2005;25 Suppl 1:S3–23.Google Scholar
  42. 42.
    Miller WJ, Baron RL, Dodd GD, 3rd, Federle MP. Malignancies in patients with cirrhosis: CT sensitivity and specificity in 200 consecutive transplant patients. Radiology 1994;193(3):645–50.PubMedGoogle Scholar
  43. 43.
    Oliver JH, 3rd, Baron RL, Federle MP, Rockette HE, Jr. Detecting hepatocellular carcinoma: value of unenhanced or arterial phase CT imaging or both used in conjunction with conventional portal venous phase contrast-enhanced CT imaging. Ajr 1996;167(1):71–7.PubMedGoogle Scholar
  44. 44.
    Jeong YY, Yim NY, Kang HK. Hepatocellular carcinoma in the cirrhotic liver with helical CT and MRI: imaging spectrum and pitfalls of cirrhosis-related nodules. Ajr 2005;185(4): 1024–32.PubMedGoogle Scholar
  45. 45.
    Takayama T, Makuuchi M, Hirohashi S, et al. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet 1990;336(8724):1150–3.PubMedGoogle Scholar
  46. 46.
    Hayashi M, Matsui O, Ueda K, et al. Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium. Ajr 1999;172(4):969–76.PubMedGoogle Scholar
  47. 47.
    Kamel IR, Liapi E, Fishman EK. Multidetector CT of hepatocellular carcinoma. Best practice & research 2005;19(1):63–89.Google Scholar
  48. 48.
    Monzawa S, Ichikawa T, Nakajima H, Kitanaka Y, Omata K, Araki T. Dynamic CT for detecting small hepatocellular carcinoma: usefulness of delayed phase imaging. Ajr 2007;188(1):147–53.PubMedGoogle Scholar
  49. 49.
    Ito K. Hepatocellular carcinoma: conventional MRI findings including gadolinium-enhanced dynamic imaging. Eur J Radiol 2006;58(2):186–99.PubMedGoogle Scholar
  50. 50.
    Naganawa S, Jenner G, Cooper TG, Potchen EJ, Ishigaki T. Rapid MR imaging of the liver: comparison of twelve techniques for single breath-hold whole volume acquisition. Radiation medicine 1994;12(6):255–61.PubMedGoogle Scholar
  51. 51.
    Semelka RC, Kelekis NL, Thomasson D, Brown MA, Laub GA. HASTE MR imaging: description of technique and preliminary results in the abdomen. J Magn Reson Imaging 1996;6(4):698–9.PubMedGoogle Scholar
  52. 52.
    Coates GG, Borrello JA, McFarland EG, Mirowitz SA, Brown JJ. Hepatic T2-weighted MRI: a prospective comparison of sequences, including breath-hold, half-Fourier turbo spin echo (HASTE). J Magn Reson Imaging 1998;8(3):642–9.PubMedGoogle Scholar
  53. 53.
    Bradley WG, Jr. Optimizing lesion contrast without using contrast agents. J Magn Reson Imaging 1999;10(3):442–9.PubMedGoogle Scholar
  54. 54.
    Helmberger TK, Schroder J, Holzknecht N, et al. T2-weighted breathold imaging of the liver: a quantitative and qualitative comparison of fast spin echo and half Fourier single shot fast spin echo imaging. Magma (New York, NY 1999;9(1–2):42–51.PubMedGoogle Scholar
  55. 55.
    Krinsky GA, Lee VS. MR imaging of cirrhotic nodules. Abdom Imaging 2000;25(5):471–82.PubMedGoogle Scholar
  56. 56.
    Mitchell DG. Focal manifestations of diffuse liver disease at MR imaging. Radiology 1992;185(1):1–11.PubMedGoogle Scholar
  57. 57.
    Ebara M, Fukuda H, Kojima Y, et al. Small hepatocellular carcinoma: relationship of signal intensity to histopathologic findings and metal content of the tumor and surrounding hepatic parenchyma. Radiology 1999;210(1):81–8.PubMedGoogle Scholar
  58. 58.
    Martin DR, Brown MA, Semelka RC. Primer on MR imaging of the abdomen and pelvis. Hoboken, N.J.: John Wiley & Sons, Inc.; 2005.Google Scholar
  59. 59.
    Matsui O, Kadoya M, Kameyama T, et al. Adenomatous hyperplastic nodules in the cirrhotic liver: differentiation from hepatocellular carcinoma with MR imaging. Radiology 1989;173(1):123–6.PubMedGoogle Scholar
  60. 60.
    Sadek AG, Mitchell DG, Siegelman ES, Outwater EK, Matteucci T, Hann HW. Early hepatocellular carcinoma that develops within macroregenerative nodules: growth rate depicted at serial MR imaging. Radiology 1995;195(3):753–6.PubMedGoogle Scholar
  61. 61.
    Mitchell DG, Rubin R, Siegelman ES, Burk DL, Jr., Rifkin MD. Hepatocellular carcinoma within siderotic regenerative nodules: appearance as a nodule within a nodule on MR images. Radiology 1991;178(1):101–3.PubMedGoogle Scholar
  62. 62.
    Hollett MD, Jeffrey RB, Jr., Nino-Murcia M, Jorgensen MJ, Harris DP. Dual-phase helical CT of the liver: value of arterial phase scans in the detection of small (< or = 1.5 cm) malignant hepatic neoplasms. Ajr 1995;164(4):879–84.PubMedGoogle Scholar
  63. 63.
    Baron RL, Oliver JH, 3rd, Dodd GD, 3rd, Nalesnik M, Holbert BL, Carr B. Hepatocellular carcinoma: evaluation with biphasic, contrast-enhanced, helical CT. Radiology 1996;199(2):505–11.PubMedGoogle Scholar
  64. 64.
    Oliver JH, 3rd, Baron RL. Helical biphasic contrast-enhanced CT of the liver: technique, indications, interpretation, and pitfalls. Radiology 1996;201(1):1–14.PubMedGoogle Scholar
  65. 65.
    Oto A, Tamm EP, Szklaruk J. Multidetector row CT of the liver. Radiologic clinics of North America 2005;43(5):827–48, vii.PubMedGoogle Scholar
  66. 66.
    Kim T, Murakami T, Takahashi S, et al. Optimal phases of dynamic CT for detecting hepatocellular carcinoma: evaluation of unenhanced and triple-phase images. Abdom Imaging 1999;24(5):473–80.PubMedGoogle Scholar
  67. 67.
    Lim JH, Choi D, Kim SH, et al. Detection of hepatocellular carcinoma: value of adding delayed phase imaging to dual-phase helical CT. Ajr 2002;179(1):67–73.PubMedGoogle Scholar
  68. 68.
    Takayasu K, Furukawa H, Wakao F, et al. CT diagnosis of early hepatocellular carcinoma: sensitivity, findings, and CT-pathologic correlation. Ajr 1995;164(4):885–90.PubMedGoogle Scholar
  69. 69.
    Hu H, He HD, Foley WD, Fox SH. Four multidetector-row helical CT: image quality and volume coverage speed. Radiology 2000;215(1):55–62.PubMedGoogle Scholar
  70. 70.
    Murakami T, Kim T, Takamura M, et al. Hypervascular hepatocellular carcinoma: detection with double arterial phase multi-detector row helical CT. Radiology 2001;218(3):763–7.PubMedGoogle Scholar
  71. 71.
    Ichikawa T, Kitamura T, Nakajima H, et al. Hypervascular hepatocellular carcinoma: can double arterial phase imaging with multidetector CT improve tumor depiction in the cirrhotic liver? Ajr 2002;179(3):751–8.PubMedGoogle Scholar
  72. 72.
    Kelekis NL, Semelka RC, Worawattanakul S, et al. Hepatocellular carcinoma in North America: a multiinstitutional study of appearance on T1-weighted, T2-weighted, and serial gadolinium-enhanced gradient-echo images. Ajr 1998;170(4):1005–13.PubMedGoogle Scholar
  73. 73.
    Peterson MS, Baron RL, Murakami T. Hepatic malignancies: usefulness of acquisition of multiple arterial and portal venous phase images at dynamic gadolinium-enhanced MR imaging. Radiology 1996;201(2):337–45.PubMedGoogle Scholar
  74. 74.
    Fujita T, Ito K, Honjo K, Okazaki H, Matsumoto T, Matsunaga N. Detection of hepatocellular carcinoma: comparison of T2-weighted breath-hold fast spin-echo sequences and high-resolution dynamic MR imaging with a phased-array body coil. J Magn Reson Imaging 1999;9(2):274–9.PubMedGoogle Scholar
  75. 75.
    Itai Y, Matsui O. Blood flow and liver imaging. Radiology 1997;202(2):306–14.PubMedGoogle Scholar
  76. 76.
    Matsui O, Kadoya M, Yoshikawa J, et al. Aberrant gastric venous drainage in cirrhotic livers: imaging findings in focal areas of liver parenchyma. Radiology 1995;197(2):345–9.PubMedGoogle Scholar
  77. 77.
    Kelekis NL, Semelka RC, Woosley JT. Malignant lesions of the liver with high signal intensity on T1-weighted MR images. J Magn Reson Imaging 1996;6(2):291–4.PubMedGoogle Scholar
  78. 78.
    Tublin ME, Dodd GD, 3rd, Baron RL. Benign and malignant portal vein thrombosis: differentiation by CT characteristics. Ajr 1997;168(3):719–23.PubMedGoogle Scholar
  79. 79.
    Yu JS, Rofsky NM. Dynamic subtraction MR imaging of the liver: advantages and pitfalls. Ajr 2003;180(5):1351–7.PubMedGoogle Scholar
  80. 80.
    Kim TK, Jang HJ, Wilson SR. Imaging diagnosis of hepatocellular carcinoma with differentiation from other pathology. Clinics in liver disease 2005;9(2):253–79.PubMedGoogle Scholar
  81. 81.
    Nguyen MH, Keeffe EB. Screening for hepatocellular carcinoma. J Clin Gastroenterol 2002;35(5 Suppl 2):S86–91.Google Scholar
  82. 82.
    Brancatelli G, Baron RL, Peterson MS, Marsh W. Helical CT screening for hepatocellular carcinoma in patients with cirrhosis: frequency and causes of false-positive interpretation. Ajr 2003;180(4):1007–14.PubMedGoogle Scholar
  83. 83.
    Choi BI, Kim CW, Han MC, et al. Sonographic characteristics of small hepatocellular carcinoma. Gastrointestinal radiology 1989;14(3):255–61.PubMedGoogle Scholar
  84. 84.
    Wernecke K, Rummeny E, Bongartz G, et al. Detection of hepatic masses in patients with carcinoma: comparative sensitivities of sonography, CT, and MR imaging. Ajr 1991;157(4): 731-9.PubMedGoogle Scholar
  85. 85.
    Cosgrove D, Blomley M. Liver tumors: evaluation with contrast-enhanced ultrasound. Abdom Imaging 2004;29(4):446–54.PubMedGoogle Scholar
  86. 86.
    Choi BI, Kim AY, Lee JY, et al. Hepatocellular carcinoma: contrast enhancement with Levovist. J Ultrasound Med 2002;21(1):77–84.PubMedGoogle Scholar
  87. 87.
    Jang HJ, Kim TK, Wilson SR. Imaging of malignant liver masses: characterization and detection. Ultrasound quarterly 2006;22(1):19–29.PubMedGoogle Scholar
  88. 88.
    Giorgio A, Ferraioli G, Tarantino L, et al. Contrast-enhanced sonographic appearance of hepatocellular carcinoma in patients with cirrhosis: comparison with contrast-enhanced helical CT appearance. Ajr 2004;183(5):1319–26.PubMedGoogle Scholar
  89. 89.
    Slattery JM, Sahani DV. What is the current state-of-the-art imaging for detection and staging of cholangiocarcinoma? The oncologist 2006;11(8):913–22.PubMedGoogle Scholar
  90. 90.
    Madariaga JR, Iwatsuki S, Todo S, Lee RG, Irish W, Starzl TE. Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases. Annals of surgery 1998;227(1): 70–9.PubMedGoogle Scholar
  91. 91.
    Lim JH. Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings. Ajr 2003;181(3):819–27.PubMedGoogle Scholar
  92. 92.
    Lim JH, Lee WJ, Takehara Y, Lim HK. Imaging of extrahepatic cholangiocarcinoma. Abdom Imaging 2004;29(5):565–71.PubMedGoogle Scholar
  93. 93.
    Robledo R, Muro A, Prieto ML. Extrahepatic bile duct carcinoma: US characteristics and accuracy in demonstration of tumors. Radiology 1996;198(3):869–73.PubMedGoogle Scholar
  94. 94.
    Kim TK, Choi BI, Han JK, Jang HJ, Cho SG, Han MC. Peripheral cholangiocarcinoma of the liver: two-phase spiral CT findings. Radiology 1997;204(2):539–43.PubMedGoogle Scholar
  95. 95.
    Magnuson TH, Bender JS, Duncan MD, Ahrendt SA, Harmon JW, Regan F. Utility of magnetic resonance cholangiography in the evaluation of biliary obstruction. Journal of the American College of Surgeons 1999;189(1):63–71; discussion -2.PubMedGoogle Scholar
  96. 96.
    Zidi SH, Prat F, Le Guen O, Rondeau Y, Pelletier G. Performance characteristics of magnetic resonance cholangiography in the staging of malignant hilar strictures. Gut 2000;46(1): 103–6.PubMedGoogle Scholar
  97. 97.
    Guarise A, Venturini S, Faccioli N, Pinali L, Morana G. Role of magnetic resonance in characterising extrahepatic cholangiocarcinomas. La Radiologia medica 2006;111(4): 526–38.PubMedGoogle Scholar
  98. 98.
    Kluge R, Schmidt F, Caca K, et al. Positron emission tomography with [(18) F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology 2001;33(5): 1029–35.PubMedGoogle Scholar
  99. 99.
    Kim YJ, Yun M, Lee WJ, Kim KS, Lee JD. Usefulness of 18F-FDG-PET in intrahepatic cholangiocarcinoma. European journal of nuclear medicine and molecular imaging 2003;30(11):1467–72.PubMedGoogle Scholar
  100. 100.
    Blackbourne LH, Earnhardt RC, Sistrom CL, Abbitt P, Jones RS. The sensitivity and role of ultrasound in the evaluation of biliary obstruction. The American surgeon 1994;60(9):683–90.PubMedGoogle Scholar
  101. 101.
    Songur Y, Temucin G, Sahin B. Endoscopic ultrasonography in the evaluation of dilated common bile duct. J Clin Gastroenterol 2001;33(4):302–5.PubMedGoogle Scholar
  102. 102.
    Tamada K, Yasuda Y, Nagai H, et al. Limitations of three-dimensional intraductal ultrasonography in the assessment of longitudinal spread of extrahepatic bile duct carcinoma. Journal of gastroenterology 2000;35(12):919–23.PubMedGoogle Scholar
  103. 103.
    Yeh BM, Breiman RS, Taouli B, Qayyum A, Roberts JP, Coakley FV. Biliary tract depiction in living potential liver donors: comparison of conventional MR, mangafodipir trisodium-enhanced excretory MR, and multi-detector row CT cholangiography–initial experience. Radiology 2004;230(3):645–51.PubMedGoogle Scholar
  104. 104.
    Stroszczynski C, Hunerbein M. Malignant biliary obstruction: value of imaging findings. Abdom Imaging 2005;30(3):314–23.PubMedGoogle Scholar
  105. 105.
    David V, Reinhold C, Hochman M, et al. Pitfalls in the interpretation of MR cholangiopancreatography. Ajr 1998;170(4):1055–9.PubMedGoogle Scholar
  106. 106.
    Kondo H, Kanematsu M, Shiratori Y, Moriwaki H, Hoshi H. Potential pitfall of MR cholangiopancreatography: right hepatic arterial impression of the common hepatic duct. Journal of computer assisted tomography 1999;23(1):60–2.PubMedGoogle Scholar
  107. 107.
    Yeh TS, Jan YY, Tseng JH, et al. Malignant perihilar biliary obstruction: magnetic resonance cholangiopancreatographic findings. Am J Gastroenterol 2000;95(2):432–40.PubMedGoogle Scholar
  108. 108.
    Rodriguez-Fernandez A, Gomez-Rio M, Medina-Benitez A, et al. Application of modern imaging methods in diagnosis of gallbladder cancer. Journal of surgical oncology 2006;93(8):650–64.PubMedGoogle Scholar
  109. 109.
    Sherlock S, Dooley J. Diseases of the liver and biliary system. 11th ed. Oxford: Blackwell Science; 2002.Google Scholar
  110. 110.
    Matsusaka S, Yamasaki H, Kitayama Y, Okada T, Maeda S. Occult gallbladder carcinoma diagnosed by a laparoscopic cholecystectomy. Surgery today 2003;33(10):740–2.PubMedGoogle Scholar
  111. 111.
    Soiva M, Aro K, Pamilo M, Paivansalo M, Suramo I, Taavitsainen M. Ultrasonography in carcinoma of the gallbladder. Acta Radiol 1987;28(6):711–4.PubMedGoogle Scholar
  112. 112.
    Levy AD, Murakata LA, Rohrmann CA, Jr. Gallbladder carcinoma: radiologic-pathologic correlation. Radiographics 2001;21(2):295–314; questionnaire, 549–55.PubMedGoogle Scholar
  113. 113.
    Gandolfi L, Torresan F, Solmi L, Puccetti A. The role of ultrasound in biliary and pancreatic diseases. Eur J Ultrasound 2003;16(3):141–59.PubMedGoogle Scholar
  114. 114.
    Sugiyama M, Atomi Y, Yamato T. Endoscopic ultrasonography for differential diagnosis of polypoid gall bladder lesions: analysis in surgical and follow up series. Gut 2000;46(2):250–4.PubMedGoogle Scholar
  115. 115.
    Kumaran V, Gulati S, Paul B, Pande K, Sahni P, Chattopadhyay K. The role of dual-phase helical CT in assessing resectability of carcinoma of the gallbladder. European radiology 2002;12(8):1993–9.PubMedGoogle Scholar
  116. 116.
    Bartlett DL, Fong Y, Fortner JG, Brennan MF, Blumgart LH. Long-term results after resection for gallbladder cancer. Implications for staging and management. Annals of surgery 1996;224(5):639–46.PubMedGoogle Scholar
  117. 117.
    Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates. Cancer 1992;70(6):1493–7.PubMedGoogle Scholar
  118. 118.
    Tsuchiya Y. Early carcinoma of the gallbladder: macroscopic features and US findings. Radiology 1991;179(1):171–5.PubMedGoogle Scholar
  119. 119.
    Kokudo N, Makuuchi M, Natori T, et al. Strategies for surgical treatment of gallbladder carcinoma based on information available before resection. Arch Surg 2003;138(7):741–50; discussion 50.PubMedGoogle Scholar
  120. 120.
    Roseau G. [The application of digestive endoscopic ultrasonography in the gallbladder pathology]. Presse Med 2004;33(14 Pt 1):954–60.PubMedGoogle Scholar
  121. 121.
    Schwartz LH, Black J, Fong Y, et al. Gallbladder carcinoma: findings at MR imaging with MR cholangiopancreatography. Journal of computer assisted tomography 2002;26(3):405–10.PubMedGoogle Scholar
  122. 122.
    Koh T, Taniguchi H, Yamaguchi A, Kunishima S, Yamagishi H. Differential diagnosis of gallbladder cancer using positron emission tomography with fluorine-18-labeled fluoro-deoxyglucose (FDG-PET). Journal of surgical oncology 2003;84(2):74–81.PubMedGoogle Scholar
  123. 123.
    Anderson CD, Rice MH, Pinson CW, Chapman WC, Chari RS, Delbeke D. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 2004;8(1):90–7.PubMedGoogle Scholar
  124. 124.
    Livraghi T, Giorgio A, Marin G, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995;197(1):101–8.PubMedGoogle Scholar
  125. 125.
    Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362(9399): 1907–17.PubMedGoogle Scholar
  126. 126.
    Rossi S, Di Stasi M, Buscarini E, et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. Ajr 1996;167(3):759–68.PubMedGoogle Scholar
  127. 127.
    Lencioni R, Pinto F, Armillotta N, et al. Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a European experience. European radiology 1997;7(4):514–9.PubMedGoogle Scholar
  128. 128.
    Buscarini L, Buscarini E, Di Stasi M, Vallisa D, Quaretti P, Rocca A. Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results. European radiology 2001;11(6):914–21.PubMedGoogle Scholar
  129. 129.
    Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003;228(1):235–40.PubMedGoogle Scholar
  130. 130.
    Mulier S, Mulier P, Ni Y, et al. Complications of radiofrequency coagulation of liver tumours. The British journal of surgery 2002;89(10):1206–22.PubMedGoogle Scholar
  131. 131.
    Kim SK, Lim HK, Kim YH, et al. Hepatocellular carcinoma treated with radio-frequency ablation: spectrum of imaging findings. Radiographics 2003;23(1):107–21.PubMedGoogle Scholar
  132. 132.
    Filippone A, Iezzi R, Di Fabio F, Cianci R, Grassedonio E, Storto ML. Multidetector-row computed tomography of focal liver lesions treated by radiofrequency ablation: spectrum of findings at long-term follow-up. Journal of computer assisted tomography 2007;31(1):42–52.PubMedGoogle Scholar
  133. 133.
    Chopra S, Dodd GD, 3rd, Chintapalli KN, Leyendecker JR, Karahan OI, Rhim H. Tumor recurrence after radiofrequency thermal ablation of hepatic tumors: spectrum of findings on dual-phase contrast-enhanced CT. Ajr 2001;177(2):381–7.PubMedGoogle Scholar
  134. 134.
    Keppke AL, Salem R, Reddy D, et al. Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. Ajr 2007;188(3):768–75.PubMedGoogle Scholar
  135. 135.
    Geschwind JF, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S194–205.PubMedGoogle Scholar
  136. 136.
    Nakamura H, Hashimoto T, Oi H, Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989;170(3 Pt 1):783–6.PubMedGoogle Scholar
  137. 137.
    Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006;131(2): 461–9.PubMedGoogle Scholar
  138. 138.
    Takayasu K, Arii S, Matsuo N, et al. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. Ajr 2000;175(3):699–704.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Unni Udayasankar
    • 1
  • Abbas Chamsuddin
    • 1
  • Pardeep Mittal
    • 1
  • William C. Small
    • 1
  1. 1.Emory University School of MedicineAtlantaUSA

Personalised recommendations